DR-299 MutSig – The incidence and co-ocurrence of genomic biomarkers in metastatic tumors
The observed incidence of cancer biomarkers can influence resource investment into key areas such as drug discovery and companion diagnostic technology. The list of clinically relevant cancer biomarkers is growing, however a systematic description of the incidence of these biomarkers is currently lacking. Understanding the prevalence of these biomarkers in late-stage cancer can be especially relevant since many companion diagnostics are utilized in the treatment of stage III and IV cancers.
By using multiple publicly available knowledge management resources that describe clinically relevant alterations, we aim to characterize the frequency of these biomarkers and contextualize their associations within the Hartwig dataset.
Eivind Hovig, University of Oslo, Norge
Back to newsMore news
Hartwig Medical Foundation welcomes new managing director
Hartwig Medical Foundation is pleased to announce that Robert Jan Lamers has joined the organization as its new managing director, …
Unraveling of genetic mechanism behind tumor formation may improve targeted treatment for cancer patients
Genetic alterations in the FGFR2 gene occur in various cancer types and represent a promising target for therapies. However, clinical …
Clinical Cancer Genomics conference, March 20-21 2025, Amsterdam
We are pleased to announce that registration for this novel exciting meeting focused on cancer whole genome and transcriptome sequencing …
The fact that the CPCT, together with Hartwig Medical Foundation, has managed to bundle data, knowledge and expertise from almost all Dutch hospitals is unique and now also deserves international attention.